Benzinga | Aug 10, 2020 07:49AM EDT

Recro Pharma Q2 EPS $(0.25) Misses $(0.16) Estimate, Sales $15.52M Miss $18.88M Estimate

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.16) by 56.25 percent. This is a 92.31 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $15.52 million which missed the analyst consensus estimate of $18.88 million by 17.79 percent. This is a 50.34 percent decrease over sales of $31.26 million the same period last year.